Changes of CD4＋ CD25＋ Regulatory T Cells in Peripheral Blood in Patients with Hepatocellular Carcinoma Before and after TACE

This study investigated the changes of CD4 CD25 regulatory T cells (Tregs) in periph-eral blood of patients with hepatocellular carcinoma before and after transcatheter arterial chemoem-bolization (TACE). The proportion of CD4 CD25 Tregs among CD4 T lymphocytes in peripheral blood of 33 patients with hepatocellular carcinoma was determined by flow cytometry before, 1 week and 1 month after TACE. And 25 healthy volunteers served as control. One month after TACE, the patients were divided into two groups: 22 in group A, who were in stable condition or getting better; and 10 in group B, who were deteriorating. One patient died and was excluded. The results showed that the percentage of CD4 CD25 Tregs among CD4 T lymphocytes did not significantly change in the 33 patients 1 week after TACE as compared with that before TACE, however, the difference was significant (P<0.01) between the patients with hepatocellular carcinoma and the healthy subjects. The percentage of CD4 CD25 Tregs among CD4 T lymphocytes in group A 1 month after TACE was decreased significantly in comparison with that before and 1 week after TACE (P<0.01), whereas, that in group B was increased significantly 1 month after TACE (P<0.01). It was concluded that patients with hepatocellular carcinoma had a higher proportion of CD4 CD25 Tregs in peripheral blood. TACE did not significantly affect the level of CD4 CD25 Tregs within short time (such as 1 week). The proportion of CD4 CD25 Tregs in peripheral blood 1 month after TACE was related to the prognosis of hepatocellular carcinoma.     

Changes of CD4＋ CD25＋ Regulatory T Cells in Peripheral Blood in Patients with Hepatocellular Carcinoma Before and after TACE

This study investigated the changes of CD4＋ CD25＋ regulatory T cells （Tregs） in periph-eral blood of patients with hepatocellular carcinoma before and after transcatheter arterial chemoem-bolization （TACE）. The proportion of CD4＋ CD25＋ Tregs among CD4＋ T lymphocytes in peripheral blood of 33 patients with hepatocellular carcinoma was determined by flow cytometry before, 1 week and 1 month after TACE. And 25 healthy volunteers served as control. One month after TACE, the patients were divided into two groups： 22 in group A, who were in stable condition or getting better; and 10 in group B, who were deteriorating. One patient died and was excluded. The results showed that the percentage of CD4＋CD25＋ Tregs among CD4＋ T lymphocytes did not significantly change in the 33 patients 1 week after TACE as compared with that before TACE, however, the difference was significant （P〈0.01） between the patients with hepatocellular carcinoma and the healthy subjects. The percentage of CD4＋ CD25＋ Tregs among CD4＋ T lymphocytes in group A 1 month after TACE was decreased significantly in comparison with that before and 1 week after TACE （P〈0.01）, whereas, that in group B was increased significantly 1 month after TACE （P〈0.01）. It was concluded that patients with hepatocellular carcinoma had a higher proportion of CD4＋CD25＋ Tregs in peripheral blood. TACE did not significantly affect the level of CD4＋ CD25＋ Tregs within short time （such as 1 week）. The proportion of CD4＋CD25＋ Tregs in peripheral blood 1 month after TACE was related to the prognosis of hepatocellular carcinoma.     

MTA1、nm23、c-myc在肝癌组织中的表达及其相关性

目的     检测肝癌组织及相应癌旁组织中MTA1、nm23、c-myc的表达,探讨三者之间的相关性及与肝癌侵袭、转移和肝癌生物学行为的关系。方法     采用免疫组织化学法检测60例肝癌组织及其相应癌旁组织中MTA1、nm23、c-myc蛋白的表达,并结合相关临床病理特征进行分析。结果    ① 肝癌组织中MTA1蛋白、c-myc蛋白的阳性表达率显著高于其相应癌旁组织（P<0.01）,而肝癌组织中nm23蛋白的阳性表达率显著低于其相应癌旁组织（P<0.01）。② 在肝癌组织中MTA1蛋白、c-myc蛋白的高表达及nm23蛋白的低表达,均与肿瘤分化程度, 肝内、外转移及门静脉癌栓相关（P<0.05）。此外,MTA1蛋白的高表达及nm23蛋白的低表达还与HBsAg水平有关（P<0.05）,c-myc蛋白的高表达还与有无肿瘤包膜有关（P<0.05）。③ Spearman相关分析显示,MTA1与nm23的表达呈负相关(rs =-0.625, P<0.01),MTA1与c-myc的表达呈正相关(rs =0.392, P<0.05),而nm23与c-myc之间未见明显相关性。结论    MTAl、c-myc蛋白水平的高表达和nm23蛋白水平的低表达与肝癌的侵袭、转移有关,三者的联合检测可用于判断肝癌的生物学行为,有助于肝癌的基础研究及临床治疗。      

肝癌组织中nm23-H1、PTEN的表达及其临床病理的意义

目的探讨nm23-H1、PTEN在肝细胞癌中的表达及其与患者的临床病理特点的关系。方法应用免疫组化S-P方法,检测50例肝癌组织中nm23-H1、PTEN的表达,分析其与临床病理之间的关系。结果 nm23-H1、PTEN蛋白阳性表达为棕黄色,定位于细胞浆。10例正常肝组织和50例癌旁肝组织均可见阳性表达。肝癌组织nm23-H1、PTEN阳性率表达分别为60%（30/50）、54%（27/50）,明显低于癌旁肝细胞阳性率表达100%（50/50,P〈0.001,P〈0.001）。nm23-H1和PTEN表达与肝癌病理分级、临床分期、肝内转移密切相关,而与患者性别、年龄、肝癌癌灶大小、肝包膜有无、甲胎蛋白水平无明显相关性。结论肝癌组织中nm23-H1、PTEN表达减低与肝癌发生发展有相关性。检测nm23-H1、PTEN两种蛋白在肝癌组织中的表达能反映肝癌的恶性程度及侵袭转移能力。     

肝细胞肝癌中血管内皮生长因子及nm23-H1蛋白的表达

目的 探讨肝细胞肝癌中与肿瘤转移相关的血管内皮生长因子（ｖａｓｕｃｌａｒ ｅｎｄｏｔｈｅｌｉａｌ ｇｒｏｗｔｈ ｆａｃｔｏｒ,ＶＥＧＦ）,ｎｍ２３－Ｈ１表达上的关系。方法 用免疫组化及图像分析的方法研究了４５例肝癌石蜡标本切片的ＶＥＧＦ,ｎｍ２３－Ｈ１的表达,进而探讨了ＶＥＧＦ的表达与ｎｍ２３－Ｈ１之间的关系。结果 ＶＥＧＦ及ｎｍ２３－Ｈ１与肝癌的转移均显相关,而二之间无相关性。结论 ＶＥＧＦ     

P-gp和nm23、P53在多原发乳腺癌组织的表达及意义

目的：研究多原发乳腺癌组织P-gp和nm23、P53变化规律，探讨P-gp和nm23、P53与多原发癌发生的关系，方法：应用免疫组化检测34例良恶性乳腺组织中P-gp、nm23、P53的表达，并比较其阳性表达率和程度的差异。结果：多原发乳腺癌和无复发乳腺癌组织P53阳性表达率均较乳腺纤维腺瘤组织高，多原发乳腺癌P53阳性表达程度高于无复发乳腺癌。结论：P53可反映癌组织细胞增殖活性，P53过表达预测第二原发癌发生具有一定价值。     

nm23基因与鼻咽癌的转移及预后的相关性

目的:探讨nm23-H1蛋白与鼻咽癌的转移及预后的相关性。方法:应用免疫组化法对180例鼻咽癌患者鼻咽癌组织nm23-H1蛋白表达进行分析。结果:nm23-H1蛋白在鼻咽癌患者中,表达阳性者转移发生率为49.8%,低于表达阴性者转移发生率为88.6%,两组比较差异有统计学意义(χ2=6.68,P<0.01)。nm23-H1蛋白表达未显示与患者年龄、性别相关。结论:nm23-H1蛋白表达可能与鼻咽癌的转移有关,对鼻咽癌预后观察有一定的意义。     

nm23、p53、PCNA在结肠癌中的表达及其临床意义

目的探讨nm23、p53、PCNA表达与结肠癌临床病理特征和预后的关系。方法运用免疫组织化学法观察46例结肠癌nm23、p53、PCNA表达。结果46例结肠癌中,高分化腺癌、中低分化腺癌的nm23检出率分别为81.8%(9/11)、62.1%(22/35),浆膜外癌细胞阳性率明显低于肌层,有、无淋巴结转移阳性表达率分别为61.1%(11/18)、85.7%(24/28)。p53在结肠癌中阳性表达率为65.2%(30/46),在浆膜外层的阳性表达率为83.3%(5/6),肌层62.5%(25/40)。p53表达与结肠癌的组织类型、分化程度和淋巴结转移未见明显相关,而与浸润深度呈正相关。PCNA该组检出率为100%,只是染色强弱有别,与病理分级、浸润与淋巴结转移未见明显相关性。结论p53和nm23表达与结肠癌的临床生物学行为密切相关,特别是与结肠癌转移和浸润深度关系密切,为结肠癌的临床治疗、手术成功率判断及肿瘤转移和转移的基因治疗提供了线索。     

胃癌组织中nm23的表达及其亚细胞组分中核苷二磷酸激酶活力的比较研究

［ 目的］ 揭示胃癌组织及相应癌旁正常组织中ｎｍ２３ 的表达及其与核苷二磷酸激酶活力的相关关系．［ 方法］ 参考了Ｍａｒｉａ Ｋｅｚｄｉ 所报道的核苷二磷酸激酶活性测定方法,应用尹宗柱等所报道的亚细胞结构分离方法分离并测定了２０ 例胃癌组织（ 转移３ 例,未转移１７ 例） 及其对应癌旁正常组织中组织匀浆液、线粒体、微粒体及细胞胞浆中核苷二磷酸激酶的酶活力,同时应用免疫组织化学法观察了ｎｍ２３ 表达阳性率．［ 结果］２０ 例胃癌原发灶中ｎｍ２３ 阳性表达率为４０ ％ ,２０ 例癌旁正常组织中阳性表达率为１０ ％ ,经卡方检验表明二者有显著性差异．胃癌组织匀浆液及胞浆中核苷二磷酸激酶活力（ 每克组织）与比活力（２６５－９９ ±８４－８１ｍ Ｕ,２－７０ ±０－９５ｍ Ｕ／ｍｇ ｐｒｏｔｅｉｎ） ;（２９０－８１±８８－１８ｍ Ｕ,３－５７ ±１－１０ｍ Ｕ／ｍｇ ｐｒｏｔｅｉｎ） 均显著高于相应癌旁正常组织的酶活力及比活力（１８１－２８±６３－６１ ,２２９－５７ ±６４－６７ｍ Ｕ;１－７５ ±０－６１ ,２－７４ ±０－７５ｍ Ｕ／ｍｇ ｐｒｏｔｅｉｎ） ;两组线粒体酶活力及比活力无显著性差异;而在微粒体中癌旁正常组织核苷二磷酸激酶活力及比活力（８?     

食管鳞癌组织中uPA、nm23的表达

目的:探讨食管鳞癌组织中uPA、nm23的表达及其与食管癌病理分级和淋巴结转移的关系。方法:应用免疫组化SP技术检测uPA及nm23在54例食管鳞癌及其癌旁和正常组织中的蛋白表达水平。结果:癌组织中uPA及nm23的阳性率分别为66.7％(36/54)和35％(19/54),uPA的表达与浸润深度和淋巴结转移呈正相关(P<0.05);nm23的表达在无淋巴结转移组明显高于有转移组(P<0.05),与浸润深度呈负相关(P<0.05)。uPA及nm23的表达呈明显负相关(x2=6.56,P<0.01)。2者均与肿瘤大小无关。结论:uPA及nm23与食管癌浸润深度和淋巴结转移关系密切。uPA与nm23联合检测以评价食管癌的转移优于单项指标。     

nm23基因在下咽癌中的表达及其意义

目的 探讨nm23基因与下咽癌组织生物学行为之间的相关性。方法 运用免疫组化二步法检测下咽癌组织中nm23单克隆抗体的表达。结果 36例下咽癌组织中nm23蛋白表达阳性率为64％。nm23蛋白表达在高、低分化肿瘤中差异有显著性（P＜0.05)，并且在发生颈淋巴结转移的肿瘤中其阳性率明显低于未发生淋巴结转移者（P＜0.05)。而与肿瘤的临床分期无明显关系（P＞0.05)。结论 nm23基因可能具有抑制下咽癌淋巴结转移的作用。     

肝细胞癌组织中PCNA和nm23的表达与转移的关系

目的 :探讨PCNA和nm2 3的表达与肝细胞癌 (HCC)转移的关系。方法 :采用免疫组织化学技术检测 5 6例HCC中PCNA和nm2 3蛋白的表达。结果 :5 6例HCC中 ,PCNA和nm2 3的表达强度均与HCC分化程度呈明显相关 ,分化愈差 ,PCNA表达愈强 ,而 nm2 3表达愈弱 ;PCNA和 nm2 3的表达强度呈明显负相关 (P <0 .0 1) ;有转移组PCNA的表达强度明显高于无转移组 (P <0 .0 1) ,而nm2 3则相反 (P <0 .0 1)。结论 :PCNA和nm2 3蛋白的表达水平能反映HCC的分化程度和发生转移的潜能 ,可作为判断HCC预后的参考指标之一